Clinical trials referenced in this document:
Funding for this research was provided by:
SciLifeLab/Knut and Alice Wallenberg national COVID-19 research program (KAW 2020.0182, KAW 2020.0241)
Swedish Heart-Lung Foundation (20210089, 20190639, 2019063)
Swedish Society of Medicine (SLS-938101)
Medical Research Council (MR/V037005/1)
Swedish Research Council (2014-02569 and 2014-07606)
Swedish Kidney Foundation (F2020-0054)
Ernfors Family Foundation
Received: 5 May 2022
Accepted: 19 August 2022
First Online: 1 September 2022
: The study was approved by the Uppsala Regional Ethical Review Agency (No. 2014/381 with amendment No. 2020–01996 and No. 2021–04798). Informed consent was obtained from each patient, or next of kin if the patient was unable to give consent. The Declaration of Helsinki and its subsequent revisions were followed. This is a prospective case control sub-study of the MR-Evaluation of Renal Function In Septic Patients (MERSEP) study, the protocol of the study was pre-registered (ClinicalTrials ID: NCT02765191), first registered May 6 2014 with a COVID-19 updated protocol registered May 7 2020 before first patient was enrolled.
: Institutional funding is accounted for separately. MH and FP are active in the American Physiological Society. The authors declare that they have no relevant competing interests.